Prosetta is a 12-year-old biotechnology company that is dedicated to the discovery, development and commercialization of innovative and cost-effective human and animal treatments and therapeutics. Prosetta applies its proprietary approach to drug discovery, based on over 25 years of research, via cell-free assembly, cellular models, drug-resin affinity chromatography and interactome analysis, that can be applied for purposes of drug discovery across a range of debilitating diseases and disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/07/15 | $31,000,000 | Series D |
Alger Management Takeda Ventures | undisclosed |
